The extract of Trachelospermum jasminoides (Lindl.) Lem. vines inhibits osteoclast differentiation through the NF-?B, MAPK and AKT signaling pathways - 28/08/20
páginas | 11 |
Iconografías | 12 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | The extract of Trachelospermum jasminoides (Lindl.) Lem. vines (TJE) inhibits osteoclast differentiation in vitro. |
• | TJE regulates osteoclastogenesis through NF-κB, MAPK and AKT signaling pathways. |
• | Network pharmacology is feasible in assisting the modernization of traditional Chinese medicine. |
Abstract |
Osteoclasts are the only cells in the body with a bone-resorption function. The identification of anti-osteoclastogenic agents is important in managing bone loss diseases. The dried vines of Trachelospermum jasminoides (Lindl.) Lem. have been used as a herbal medicine to treat musculoskeletal soreness in East Asia for hundreds of years. In the present study, we focused on the effect of Trachelospermum jasminoides (Lindl.) Lem. extract (TJE) on osteoclast differentiation. As indicated by tartrate-resistant acid phosphatase (TRAP) staining, TJE inhibited osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand from bone marrow-derived monocytes/macrophages without showing any cytotoxicity. In addition, TJE effectively suppressed F-actin ring formation and the bone-resorption function of osteoclasts. The subsequent studies such as network pharmacology and molecular investigation, revealed that TJE inhibited osteoclastogenesis-related genes in a dose- and time-dependent manner through NF-κB, MAPK and AKT-mediated mechanism followed by the nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)/c-Fos pathway. Our study could potentially explain the underlying molecular pharmacology of TJE in osteoclast-related diseases. What’s more, it suggested that network pharmacology could help the modernization of traditional Chinese medicine.
El texto completo de este artículo está disponible en PDF.Keywords : Trachelospermum jasminoides (Lindl.) Lem, Osteoclast differentiation, Network pharmacology, NF-κB, MAPK, AKT
Esquema
Vol 129
Artículo 110341- septembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?